Mechanisms, evidence and limitations — including the difference between a research compound and an approved medicine.
Tissue-repair research
The Wolverine Stack
BPC-157 + TB-500
RESEARCH-USE ONLY · NOT FDA-APPROVED
BPC-157 has been studied in animals for tendon, ligament and muscle healing and blood-vessel growth. TB-500 is a thymosin beta-4 fragment studied for cell migration and tissue remodeling; findings on full-length thymosin beta-4 do not establish benefits of TB-500.
What the evidence supports
Evidence is mostly preclinical. Reliable human trials have not established that this combination repairs injuries safely or effectively. The extended four-peptide version adds CJC-1295 + ipamorelin, but its combined benefit and safety are unproven.
Regulatory & safety context
FDA flags safety uncertainties for both compounds, including impurities and immune reactions. BPC-157 and TB-500 are prohibited by WADA in and out of competition. Research-use-only materials are not for human treatment.
Growth-hormone research
CJC-1295 + Ipamorelin
GHRH analogue + ghrelin-receptor agonist
INVESTIGATIONAL · NOT FDA-APPROVED
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue; ipamorelin acts at the ghrelin receptor. They target endogenous growth-hormone release. Natural GH pulses often occur during sleep, but a reliably overnight or physiologic effect of this stack is not established; CJC formulations differ.
What the evidence supports
Small human studies of individual compounds do not prove that the combination improves sleep, recovery, body composition or aging. Claims that it is the most widely used or optimizes GH are not established clinical evidence.
Regulatory & safety context
FDA compounding evaluation and advisory review are not drug approval or blanket permission to compound. Ipamorelin was reviewed by the advisory committee in 2024; current eligibility depends on the exact substance, route and applicable law. FDA reports safety concerns, including serious adverse events. Both are WADA-prohibited.
Visceral-fat research
Tesamorelin
GHRH analogue · Egrifta
FDA-APPROVED FOR A SPECIFIC INDICATION
Egrifta (tesamorelin) is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight-loss management or anti-aging.
What the evidence supports
Phase 3 trials in that specific population reported roughly 15–18% reductions in visceral adipose tissue over 26 weeks, not 15–18% body-weight loss. Results do not establish the same benefit in otherwise healthy adults. Combining it with CJC-1295 + ipamorelin for body recomposition is not an FDA-approved or well-validated regimen.
Regulatory & safety context
Approval applies to the branded product and its labeled indication, not compounded versions or peptide stacks. Risks include elevated IGF-1, fluid retention and glucose intolerance; active malignancy is a contraindication. Long-term cardiovascular safety is not established.
Sleep & recovery research
Sermorelin + Ipamorelin
GHRH fragment + GH secretagogue
COMBINATION NOT FDA-APPROVED
Sermorelin is the 29-amino-acid, shortest fully active GHRH fragment and has a history of clinical use. Ipamorelin targets the ghrelin receptor. The combination is discussed in relation to sleep, recovery and healthy-aging goals.
What the evidence supports
Historical use of sermorelin does not establish this stack as gentler, safer or effective for anti-aging. High-quality trials of the combination for these goals are lacking; a longer track record does not guarantee results.
Regulatory & safety context
Historical sermorelin product approvals do not approve this combination or a compounded formulation. Ipamorelin has FDA-identified safety uncertainties and compounding restrictions. GH-releasing factors are WADA-prohibited.
Skin & collagen research
GHK-Cu
Copper-binding tripeptide
NOT FDA-APPROVED AS A THERAPEUTIC DRUG
GHK-Cu is studied for skin remodeling, collagen-related processes and wound biology. Topical cosmetic research and injectable use are different contexts and cannot be treated as interchangeable.
What the evidence supports
Laboratory findings and limited topical human studies do not establish injectable benefits or longer life. Pairing GHK-Cu with a GH secretagogue for anti-aging is unproven, with no established combined efficacy or safety.
Regulatory & safety context
FDA identifies limited human safety data and immune-reaction risks for injectable GHK-Cu. Non-injectable GHK-Cu is under FDA compounding evaluation, with advisory consultation planned by February 2027; this is not approval.
Longevity research
Epitalon + CJC-1295 + Ipamorelin
Investigational longevity stack
INVESTIGATIONAL · NOT FDA-APPROVED
Epitalon is investigated in cell and animal models for telomerase-related and aging biology. CJC-1295 and ipamorelin target growth-hormone pathways. Combining these mechanisms does not demonstrate clinical synergy.
What the evidence supports
Robust human trials have not established longer lifespan, reversed aging or improved healthspan from this stack. Preclinical telomere findings should not be presented as human anti-aging outcomes.
Regulatory & safety context
Neither this stack nor its investigational components are FDA-approved. FDA highlights missing epitalon safety information and peptide impurity/immune-reaction risks, as well as concerns for CJC-1295 and ipamorelin. Compounding legality must be checked independently of physician evaluation.
